ArticleEJNMMI research2026
Fractionation gives therapeutic benefit in animal model of [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical standard practice of [177Lu]Lu-PSMA-617 therapy is a single injection per treatment cycle, with 6 weeks between cycles. While clinical schedules currently utilize single-bolus cycles, splitting a treatment cycle into multiple smaller injections has demonstrated benefits in other radionuclide therapies, preclinically and in clinical studies. Potential mechanisms for improved therapeutic efficacy include receptor recycling, receptor upregulation, or targeting new cell growth between fractions. This study aims to investigate the effects on tumor size and animal survival, in a mouse model of prostate cancer, of fractionating [177Lu]Lu-PSMA-617 therapy compared to the same total activity in a single injection.
resultsBALB/c mice bearing subcutaneous LNCaP prostate cancer tumors, below 650 mm3 in volume, were treated with either 1 × 30 MBq, 2 × 15 MBq (24-hour window), or 2 × 15 MBq (6-day window). SPECT/CT imaging showed a higher, but not significantly so, tumor uptake in the 24-hour window group than in the unfractionated one. Differences in tumor sizes were primarily visible during regrowth after therapy, with significantly smaller relative tumor sizes in the 24-hour window group compared to the unfractionated group day 89–95 post inoculation. The median survival for the 24-hour group (71.5 days) was significantly longer than that of the unfractionated group (46 days; p = 0.024). The 6-day group tumor sizes and survival came close to the 24-hour one, but was not significantly better than the unfractionated group.
conclusionThis study demonstrates that fractionation gives therapeutic benefit in an animal model of [177Lu]Lu-PSMA-617 therapy of prostate cancer for tumors in this size range. A shorter 24-hour window outperformed a longer of 6 d between fractions. The outlook for clinical translation will depend on if the mechanism is relevant at conditions, blood ligand concentration etc., that differs between the animal model and human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.